Merck Unveils New MAVENCLAD Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity
September 13, 2024,Darmstadt, Germany : Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine tablets) in individuals with relapsing multiple sclerosis (RMS). Among 34 total MAVENCLAD presentations are data from several MAGNIFY-MS …